Employees: 02 (2023.0)Legal category: 5485Size: PMECreation date: 2018-10-19 (7 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: CRETEIL (94000), Val-de-Marne
SELARL PHARMACIE INGANI : revenue, balance sheet and financial ratios
SELARL PHARMACIE INGANI is a French company
founded 7 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in CRETEIL (94000),
this company of category PME
shows in 2022 a revenue of 1.6 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - SELARL PHARMACIE INGANI (SIREN 844097907)
Indicator
2024
2023
2022
2021
2020
2019
Revenue
N/C
N/C
1 622 440 €
N/C
1 493 530 €
1 413 200 €
Net income
79 978 €
37 157 €
136 035 €
153 033 €
116 299 €
91 781 €
EBITDA
N/C
N/C
190 179 €
N/C
168 920 €
124 649 €
Net margin
N/C
N/C
8.4%
N/C
7.8%
6.5%
Revenue and income statement
In 2024, SELARL PHARMACIE INGANI generates positive net income of 80 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2019-2024: 92 k€ -> 80 k€.
Net income (2024)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
79 978 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 74%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 49%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2024)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
74.235%
Financial autonomy (2024)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
49.301%
Asset age ratio (2024)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2019
2020
2021
2022
2023
2024
Debt ratio
495.781
307.749
185.7
133.363
96.333
74.235
Financial autonomy
13.914
21.732
28.74
37.237
41.504
49.301
Repayment capacity
10.802
7.768
None
5.455
None
None
Cash flow / Revenue
6.228%
8.158%
None%
8.705%
None%
None%
Sector positioning
Debt ratio
74.232024
2022
2023
2024
Q1: 16.46
Med: 58.48
Q3: 154.77
Average-10 pts over 3 years
In 2024, the debt ratio of SELARL PHARMACIE INGANI (74.23) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
Financial autonomy
49.3%2024
2022
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Average+12 pts over 3 years
In 2024, the financial autonomy of SELARL PHARMACIE INGANI (49.3%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
Repayment capacity
5.46 years2022
2022
Q1: 1.29 years
Med: 3.55 years
Q3: 6.63 years
Average
In 2022, the repayment capacity of SELARL PHARMACIE INGANI (5.46) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 247.75. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2024)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2019
2020
2021
2022
2023
2024
Liquidity ratio
179.182
292.306
231.874
307.084
204.134
247.747
Interest coverage
7.064
4.381
None
3.624
None
None
Sector positioning
Liquidity ratio
247.752024
2022
2023
2024
Q1: 129.46
Med: 182.14
Q3: 260.79
Good
In 2024, the liquidity ratio of SELARL PHARMACIE INGANI (247.75) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
Interest coverage
3.62x2022
2022
Q1: 0.75x
Med: 2.51x
Q3: 5.16x
Good
In 2022, the interest coverage of SELARL PHARMACIE INGANI (3.6x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2024)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2024)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2024)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2024)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution SELARL PHARMACIE INGANI
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2019
2020
2021
2022
2023
2024
Operating WCR
80 256 €
130 385 €
0 €
184 796 €
0 €
0 €
Inventory turnover (days)
19
23
0
25
0
0
Customer payment term (days)
7
4
0
5
0
0
Supplier payment term (days)
41
43
0
50
0
0
Positioning of SELARL PHARMACIE INGANI in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 225 transactions of similar company sales
in 2024,
the value of SELARL PHARMACIE INGANI is estimated at
1 116 552 €
(range 777 549€ - 1 670 425€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2024
225 transactions
777k€1116k€1670k€
1 116 552 €Range: 777 549€ - 1 670 425€
NAF 5 année 2024
Valuation method used
Net Income Multiple
79 978 €
×
14.0x
=1 116 552 €
Range: 777 549€ - 1 670 426€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare SELARL PHARMACIE INGANI with other companies in the same sector:
Frequently asked questions about SELARL PHARMACIE INGANI
What is the revenue of SELARL PHARMACIE INGANI ?
The revenue of SELARL PHARMACIE INGANI in 2022 is 1.6 M€.
Is SELARL PHARMACIE INGANI profitable?
Yes, SELARL PHARMACIE INGANI generated a net profit of 80 k€ in 2024.
Where is the headquarters of SELARL PHARMACIE INGANI ?
The headquarters of SELARL PHARMACIE INGANI is located in CRETEIL (94000), in the department Val-de-Marne.
Where to find the tax return of SELARL PHARMACIE INGANI ?
The tax return of SELARL PHARMACIE INGANI is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does SELARL PHARMACIE INGANI operate?
SELARL PHARMACIE INGANI operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart